This company listing is no longer active
Zymergen (ZY) Stock Overview
Zymergen Inc. design, develop, and commercialize microbes, molecules, and materials. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
ZY Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
An Undervalued 3.3Moz Gold Project in Canada
Key takeaways Upside Gold is developing the Kena Gold Project, near the town of Nelson in the Kootenays region of southern British Columbia. Kena hosts a historical gold resource of 3.33 million ounces (561,000 ounces Indicated and 2.77 million ounces Inferred) across a 10,200-hectare land package.Read more
Zymergen Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$2.43 |
| 52 Week High | US$11.87 |
| 52 Week Low | US$1.10 |
| Beta | 0 |
| 1 Month Change | -6.90% |
| 3 Month Change | 21.50% |
| 1 Year Change | -76.75% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -93.55% |
Recent News & Updates
Zymergen chief scientific officer to depart as company lays off more employees
Aug 25Zymergen: Ginkgo Bioworks Acquisition
Jul 26Zymergen expands agreement with Octant on developing breakthrough medicines
Jul 14Recent updates
Zymergen chief scientific officer to depart as company lays off more employees
Aug 25Zymergen: Ginkgo Bioworks Acquisition
Jul 26Zymergen expands agreement with Octant on developing breakthrough medicines
Jul 14Zymergen Seeks Turnaround But Runway Is Running Low
Jun 03Zymergen: A Humbled Company With A Business On The Ropes
May 23Some Zymergen Inc. (NASDAQ:ZY) Analysts Just Made A Major Cut To Next Year's Estimates
Mar 27
Zymergen Inc. (NASDAQ:ZY) Consensus Forecasts Have Become A Little Darker Since Its Latest Report
Mar 25Zymergen: Total Chaos
Dec 09Zymergen: How To Buy A Disaster
Aug 05Analysts Just Made A Major Revision To Their Zymergen Inc. (NASDAQ:ZY) Revenue Forecasts
Aug 05Shareholder Returns
| ZY | US Chemicals | US Market | |
|---|---|---|---|
| 7D | 3.4% | 3.3% | -0.6% |
| 1Y | -76.7% | 6.7% | 16.0% |
Return vs Industry: ZY underperformed the US Chemicals industry which returned -15.1% over the past year.
Return vs Market: ZY underperformed the US Market which returned -23.7% over the past year.
Price Volatility
| ZY volatility | |
|---|---|
| ZY Average Weekly Movement | 13.3% |
| Chemicals Industry Average Movement | 7.4% |
| Market Average Movement | 7.1% |
| 10% most volatile stocks in US Market | 16.4% |
| 10% least volatile stocks in US Market | 3.3% |
Stable Share Price: ZY's share price has been volatile over the past 3 months.
Volatility Over Time: ZY's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2013 | 505 | n/a | www.zymergen.com |
Zymergen Inc. design, develop, and commercialize microbes, molecules, and materials. It offers an automation solution comprising reconfigurable automation carts, a modular hardware building blocks that allow for assembly of work cells customized for the particular needs of a lab; and automation control software, a cloud-based software used to control integrated automation systems. It serves electronics, packaging, healthcare, agriculture, and other industries.
Zymergen Inc. Fundamentals Summary
| ZY fundamental statistics | |
|---|---|
| Market cap | US$253.58m |
| Earnings (TTM) | -US$364.92m |
| Revenue (TTM) | US$14.58m |
Is ZY overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ZY income statement (TTM) | |
|---|---|
| Revenue | US$14.58m |
| Cost of Revenue | US$178.03m |
| Gross Profit | -US$163.45m |
| Other Expenses | US$201.47m |
| Earnings | -US$364.92m |
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -3.50 |
| Gross Margin | -1,121.15% |
| Net Profit Margin | -2,503.04% |
| Debt/Equity Ratio | 0% |
How did ZY perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2022/10/23 02:41 |
| End of Day Share Price | 2022/10/18 00:00 |
| Earnings | 2022/06/30 |
| Annual Earnings | 2021/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Zymergen Inc. is covered by 5 analysts. of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Derik de Bruin | BofA Global Research |
| Matthew Sykes | Goldman Sachs |
| Sriharsha Pappu | HSBC |